J&J Thinks It Can Win Over Biosimilar Competition
The big pharma reports strong 2Q earnings and executives talk about strategy for defending against biosimilar competition in the US.
The big pharma reports strong 2Q earnings and executives talk about strategy for defending against biosimilar competition in the US.